Objective: Studies summarizing the outcome of first-trimester septated cystic hygroma are generally based on small studies or from multiple centers with limited ascertainment. We reviewed the natural history of a large cohort of such cases from a single tertiary referral center, with the aim being to establish contemporary outcome data, particularly in the setting of normal karyotype. Methods: A retrospective cohort study from 2007 to 2017 was conducted at a single tertiary referral prenatal diagnosis center. Data were analyzed from a prospectively collated fetal anomaly database. Search terms were “increased nuchal translucency (NT),” “cystic hygroma,” and “septated cystic hygroma.” All cases were confirmed to have NT >3 mm with septations. Cases of simple increased NT without septations were excluded. Results: During the study period, over 110,000 pregnancies were delivered at our center, resulting in 410 cases of septated cystic hygroma diagnosed prior to 14 weeks’ gestation. Pregnancy outcome was obtained in 99% (405/410) of cases, with detailed pathology outcome available in 92% (378/410). A total of 87% (351/405) underwent invasive prenatal testing, and postnatal chromosome status was established in further 27 cases. A total of 61% (230/378) had abnormal chromosomal status. Of the 39% (148/378) with normal chromosomal status, only 13% (19/148) had a significant structural fetal abnormality, which included 7 cardiac and 12 noncardiac abnormalities. Overall, the perinatal loss was 62% (253/405). The total survival rate in the setting of euploid cystic hygroma without structural abnormality was 84% (108/129). Conclusions: Counseling regarding outcomes in the setting of first-trimester septated cystic hygroma initially focuses on the strong likelihood of an abnormal karyotype, which occurs in 61% of cases. However, once fetal chromosomal abnormality is excluded, our results demonstrate only a 13% incidence of major structural fetal abnormality, which appears significantly less than previously reported. Normal fetuses have a 77% survival rate. These data represent the largest single-center study of first-trimester cystic hygroma with complete outcome data and therefore will be useful for contemporary patient counseling. Such counseling can be more positive than previously expected, once chromosomal abnormality is first excluded.

1.
Malone
FD
,
Ball
RH
,
Nyberg
DA
,
Comstock
CH
,
Saade
GR
,
Berkowitz
RL
,
First-trimester septated cystic hygroma: prevalence, natural history, and pediatric outcome
.
Obstet Gynecol
.
2005
;
106
:
288
94
. ..
2.
Graesslin
O
,
Derniaux
E
,
Alanio
E
,
Gaillard
D
,
Vitry
F
,
Quéreux
C
,
Characteristics and outcome of fetal cystic hygroma diagnosed in the first trimester
.
Acta Obstet Gynecol Scand
.
2007
;
86
:
1442
6
. ..
3.
Ducarme
G
,
Graesslin
O
,
Alanio
E
,
Bige
V
,
Gaillard
D
,
Gabriel
R
.
Increased nuchal translucency and cystic hygroma in the first trimester: prenatal diagnosis and neonatal outcome
.
Gynecol Obstet Fertil
.
2005
;
33
:
750
4
.
4.
Sanhal
CY
,
Mendilcioglu
I
,
Ozekinci
M
,
Yakut
S
,
Merdun
Z
,
Simsek
M
,
Prenatal management, pregnancy and pediatric outcomes in fetuses with septated cystic hygroma
.
Braz J Med Biol Res
.
2014
;
47
:
799
803
. ..
5.
Ali
MM
,
Chasen
ST
,
Norton
ME
.
Testing for Noonan syndrome after increased nuchal translucency
.
Prenat Diagn
.
2017
;
37
:
750
3
. ..
6.
Razzaque
MA
,
Komoike
Y
,
Nishizawa
T
,
Inai
K
,
Furutani
M
,
Higashinakagawa
T
,
Characterization of a novel KRAS mutation identified in Noonan syndrome
.
Am J Med Genet A
.
2012
;
158A
:
524
32
. .
7.
Wapner
RJ
,
Martin
CL
,
Levy
B
,
Ballif
BC
,
Eng
CM
,
Zachary
JM
,
Chromosomal microarray versus karyotyping for prenatal diagnosis
.
N Engl J Med
.
2012
;
367
:
2175
84
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.